Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/48377
Title: | Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis |
Authors: | WOLLENBERG, Andreas; MARCOUX, Danielle; I, Jonathan Silverberg; AOKI, Valeria; BASELGA, Eulalia; ZHANG, Haixin; LEVIT, Noah A.; TAIEB, Alain; ROSSI, Ana B. |
Citation: | ACTA DERMATO-VENEREOLOGICA, v.102, article ID adv00726, 8p, 2022 |
Abstract: | This post hoc analysis examined SCORing Atopic Dermatitis (SCORAD) outcomes in 471 paediatric patients (children age 6-<12 years, n = 304; adolescents age 12-<18 years, n = 167) with atopic dermatitis treated with dupilumab, +/- topical corticosteroids, in two 16-week phase 3 randomized controlled trials and a 1-year interim data cut of a subsequent open-label extension study. Paediatric patients treated with dupilumab (+/- topical corticosteroids) had significantly lower SCORAD, objective SCORAD (o-SCORAD), and individual SCORAD components from week 3 to 16 compared with placebo (+/- topical corticosteroids) in the randomized controlled trials. The results were sustained or continuously improved over 1 year of open-label treatment with dupilumab +/- topical corticosteroids. SCORAD-50 was achieved in almost all patients (91.3-91.8%) by week 52 with continued dupilumab treatment across age groups. Almost all (> 86%) patients achieved mild or absent pruritus and sleep loss at week 52. In conclusion, dupilumab +/- topical corticosteroids resulted in rapid and significant improvements in all aspects of SCORAD analysed, and the results were sustained over 1 year. |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - FM/MDT Artigos e Materiais de Revistas Científicas - LIM/56 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_WOLLENBERG_Dupilumab_Provides_Rapid_and_Sustained_Improvement_in_SCORing_2022.PDF | publishedVersion (English) | 12.64 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.